Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H20FN2O4S.Na |
| Molecular Weight | 438.448 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[O-]C(=O)CCN1C2=C(C[C@@H](CC2)NS(=O)(=O)C3=CC=C(F)C=C3)C4=C1C=CC=C4
InChI
InChIKey=JRBVAOJTPBHRQQ-XFULWGLBSA-M
InChI=1S/C21H21FN2O4S.Na/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26;/h1-6,8-9,15,23H,7,10-13H2,(H,25,26);/q;+1/p-1/t15-;/m1./s1
| Molecular Formula | Na |
| Molecular Weight | 22.9898 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C21H20FN2O4S |
| Molecular Weight | 415.458 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Ramatroban is a dual antagonist of thromboxane A2 receptor and PGD2 receptor. The drug was developed by Bayer and tested for the treatment of asthma and allergic rhinitis. In Japan ramatroban reached final approval and is being marketed under the name Baynas. In vitro studies have shown that the drug effectively inhibits smooth muscle cells contraction.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Binding characteristics of the new thromboxane A2/prostaglandin H2 receptor antagonist [3H]BAY U 3405 to washed human platelets and platelet membranes. | 1992 Aug 4 |
|
| Differential effects of prostacyclin and iloprost in the isolated carotid artery of the guinea-pig. | 2001 Aug 24 |
|
| Participation of chemical mediators other than histamine in nasal allergy signs: a study using mice lacking histamine H(1) receptors. | 2002 Aug 9 |
|
| The role of chemical mediators in eosinophil infiltration in allergic rhinitis in mice. | 2003 Apr |
|
| Chemoattractant receptor-homologous molecule expressed on Th2 cells activation in vivo increases blood leukocyte counts and its blockade abrogates 13,14-dihydro-15-keto-prostaglandin D2-induced eosinophilia in rats. | 2003 Nov |
|
| Participation of chemical mediators in the development of experimental allergic conjunctivitis in rats. | 2004 Nov |
|
| Structural determinants of arylacetic acid nonsteroidal anti-inflammatory drugs necessary for binding and activation of the prostaglandin D2 receptor CRTH2. | 2005 Mar |
|
| Prostaglandin D2-induced eosinophilic airway inflammation is mediated by CRTH2 receptor. | 2005 Mar |
|
| CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist responses. | 2005 Nov 7 |
|
| Identification of determinants of ligand binding affinity and selectivity in the prostaglandin D2 receptor CRTH2. | 2005 Sep 16 |
|
| Involvement of cyclooxygenase-2 in allergic nasal inflammation in rats. | 2006 Nov |
|
| Zwitterionic CRTh2 antagonists. | 2011 Mar 24 |
|
| Discovery of potent, selective, and orally bioavailable alkynylphenoxyacetic acid CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases. | 2011 Oct 27 |
Patents
Sample Use Guides
75 mg is administered orally devided in two doses, after breakfast and after dinner (or before going to bed).
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 22:59:52 UTC 2023
by
admin
on
Wed Jul 05 22:59:52 UTC 2023
|
| Record UNII |
5J3I129AXS
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1040405-44-4
Created by
admin on Wed Jul 05 22:59:52 UTC 2023 , Edited by admin on Wed Jul 05 22:59:52 UTC 2023
|
PRIMARY | |||
|
67027609
Created by
admin on Wed Jul 05 22:59:52 UTC 2023 , Edited by admin on Wed Jul 05 22:59:52 UTC 2023
|
PRIMARY | |||
|
5J3I129AXS
Created by
admin on Wed Jul 05 22:59:52 UTC 2023 , Edited by admin on Wed Jul 05 22:59:52 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |